Astellas Pharma and Osaka University collaborate to develop cartilage organoid cell therapy for intervertebral disc degenerative disease.

Astellas Pharma and Osaka University start research collaboration to develop pluripotent stem cell-derived cartilage organoid cell therapy for intervertebral disc degenerative disease. Astellas Institute for Regenerative Medicine (AIRM) and Osaka University aim to combine cartilage tissue creation protocol with Universal Cells' UDC and AIRM's cell therapy expertise, leveraging Universal Cells' Universal Donor Cell technology.